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Objectives: Fungi, particularly Aspergillus and Candida species, are increasingly
found in cystic ﬁbrosis (CF) airway ﬂuids. However, their relationship to other
CF pathogens, medications and lung function, especially in CF children, remains
poorly understood. To address this question, we analyzed the associations of fungal
colonization with microbiological and clinical parameters of pediatric CF patients.
Methods: Fungal colonization was categorized in n = 128 CF patients based on
Chotirmall et al. (Chest 2010). Candida albicans (CA) was the most prevalent
fungus detected in CF airway ﬂuids, followed by C. non-albicans > Aspergillus
fumigatus (AF) > A. non-fumigatus species. Colonization with CA correlated
positively with age, inhaled antibiotic use, and Aspergillus species, while an inverse
correlation with Haemophilus and no association with S. aureus or Pseudomonas
was found. Colonization with AF correlated positively with age, inhaled antibiotics,
Pseudomonas, Stenotrophomonas, atypical mycobacteria and CF-related diabetes
and inversely with Haemophilus. ABPA showed no correlation with AF coloniza-
tion, but with non-fumigatus species and use of azithromycin. Colonization with
AF or CA correlated inversely with cross-sectional FEV1, but not with MEF25.
Colonization with AF correlated with longitudinal FEV1 decline.
Conclusion: This study suggests that colonization with CA or AF is affected by
bacterial co-colonization and may modulate lung function already in pediatric CF.
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Objectives: Changes in the weather are associated with adverse outcomes in asthma
and COPD but have been little studied in CF. We conducted a prospective study to
investigate the impact of climate and season on rates of viral respiratory infection
(VRI) and pulmonary exacerbation (PEx) in adults with CF.
Methods: 98 adults with CF living in North-West England were followed for
12 months. Patients were seen every 2 months and additionally at onset of PEx.
Sputum, nose- and throat-swabs were tested at each visit for 9 respiratory viruses
using PCR assays. Hourly temperature and relative humidity measurements in
central Manchester were recorded. Data were analysed with generalised estimating
equation models.
Results: 29% and 37% of visits met criteria for VRI and PEx respectively. Rhi-
novirus accounted for 72% of viruses. Incidence of rhinovirus was high throughout
the year but peaked in autumn. Rates of other viruses peaked in winter and
were very low during summer. Rhinovirus infection was associated with higher
mean temperatures (OR 1.08; 95%CI 1.03–1.13; p = 0.001) and lower relative
humidity (OR 0.98; 95%CI 0.96–0.997; p = 0.02). Non-rhinovirus VRI was strongly
associated with lower mean temperatures (OR 0.87; 95%CI 0.83–0.92; p< 0.001)
and higher weekly relative humidity (OR 1.05; 95%CI 1.01–1.08; p = 0.007). There
was no signiﬁcant association between incidence of PEx and climate variables. The
incidence of PEx and antibiotic usage overall did not display seasonal variability.
Conclusion: There is a clear seasonal pattern to VRI in adults with CF. The
incidence of VRI but not PEx is associated with changes in weather conditions.
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Introduction: In Cystic Fibrosis (CF) improving physical activity (PA) increases
sputum clearance, respiratory muscle strength and leads to better quality of life.
Recent studies have shown that the level of daily physical activity may have a
positive impact on exercise tolerance, on nutritional status and on the rate of decline
of FEV1.
Aims: To date there is relatively little information about objectively measured
habitual physical activity in CF.
Methods: Twenty stable CF patients (mean age 33±8SD yrs; FEV1 2.6±0.6 l),
were studied at rest and during symptom-limited incremental exercise test (CPET)
and during 6MWT. Daily physical activity was assessed by means of: (1) an ac-
celerometer (SenseWear, SW), that subjects wore for 4 consecutive days, including
weekends, and (2) the Habitual Activity Estimation Scale Questionnaire (HAESQ).
Results: There was no difference between the weekdays and weekends recordings
in any activity variable. We found no agreement in physical activity measured by
SW vs HAESQ. We found a close relationship between SW energy expenditure and
FEV1 during both weekdays and weekend (r = 0.52; p = 0.01 and r = 0.51; p = 0.02)
and SW activities of moderate intensity vs VO2 peak (r = 0.5; p = 0.02) at CPET.
Distance at 6MWT was not correlated to any physical activity variables, either at
SW or HAESQ.
Conclusions: Adults with CF have similar levels of activity at weekends and
weekdays. Activity levels measured by the subjective methods and by the objective
monitoring, i.e., SW vs HAESQ, seems to provide different information on the
habitual daily physical activity. Physical activity is related to the maximum exercise
capacity and to the degree of the airﬂow obstruction.
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RSV causes considerable morbidity and mortality in children. In cystic ﬁbrosis (CF)
viral infections are associated with worsening respiratory symptoms and bacterial
colonization. Palivizumab is effective in reducing RSV hospitalisation in high risk
patient groups. Evidence regarding its effectiveness and safety in CF is inconclusive.
CF screening in N. Ireland enabled timely palivizumab prophylaxis, becoming
routine in 2002.
Objectives: To determine the effect of palivizumab on hospitalization for RSV in
the ﬁrst year and compare lung function and bacterial colonization at age 6 yrs for
those born before (‘pre’) and after (‘post’) palivizumab prophylaxis was introduced.
Methods: A retrospective review was conducted for all patients diagnosed with
CF over a 10 year period from 1998 to 2007. Hospitalization for RSV and time
to Pseudomonas (PA) 1st isolate, lung function and growth parameters aged 6 yrs
were recorded. Comparisons were made for outcomes pre and post introduction of
palivizumab.
Results: 82 children were included; 37 pre and 45 post palivizumab. 8 children pre
and 2 post required hospitalization for RSV infection (median stay 9 vs 3 days).
PA 1st isolate was signiﬁcantly earlier in the post vs pre group (median 85 vs
144 months), p< 0.0001. Chronic PA infection at 6 yrs remains low in both groups.
We found similar rates of Staph Aureus infection, FEV1 and growth parameters at
6 yrs.
Conclusion: Palivizumab was effective in reducing number and duration of RSV
related hospitalization. Surprisingly, we found a signiﬁcantly earlier time to 1st
isolate of PA in palivizumab recipients which we could not explain by altered or
improved diagnostic tests.
